The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...

Population-based cohort study identifies better treatment objectives for women with advanced-stage ovarian cancer. Toxicity management and quality of life should be prioritized over treatment to ...

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...

evaluated neoadjuvant nivolumab plus chemotherapy. The study demonstrated statistically significant and clinically meaningful improvements in event-free survival and pathological complete response ...

Bin Yu; Jin Zhou; Hongzhou Cai; Ting Xu; Zicheng Xu; Qing Zou; Min Gu ...

Associations between age at diagnosis and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer. Patients who received NACT and UBS and associated delays by sub-cohort (n = ...

Neoadjuvant platinum-based chemotherapy improves structure preservation (SP) for patients with T3, T4a, and selected T4b ...

Data suggest that neoadjuvant immune checkpoint inhibitor (ICI) therapy improves outcomes in patients with early-stage triple-negative breast cancer, but adjuvant ICI therapy does not.

The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.

The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.

The role of income level in outcomes and treatment for patients with fibrolamellar hepatocellular carcinoma.